In contrast, a study in rheumatoid arthritis patients showed that tofacitinib inhibits the secretion of both IL-17 and IFN-γ in anti-CD3/anti-CD28 stimulated CD4+ T cells [48]. Here, IL17A is linked to rheumatoid arthritis.